8,205 Shares in Omeros Co. (NASDAQ:OMER) Purchased by US Bancorp DE

US Bancorp DE purchased a new position in Omeros Co. (NASDAQ:OMER) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 8,205 shares of the biopharmaceutical company’s stock, valued at approximately $81,000.

A number of other institutional investors also recently bought and sold shares of OMER. New York State Common Retirement Fund boosted its holdings in Omeros by 245.4% in the fourth quarter. New York State Common Retirement Fund now owns 17,313 shares of the biopharmaceutical company’s stock valued at $171,000 after purchasing an additional 12,300 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in shares of Omeros in the 4th quarter valued at about $121,000. Stordahl Capital Management Inc. purchased a new stake in shares of Omeros in the fourth quarter worth about $395,000. Seros Financial LLC purchased a new stake in shares of Omeros in the fourth quarter worth about $159,000. Finally, SG Americas Securities LLC grew its holdings in Omeros by 21.2% during the fourth quarter. SG Americas Securities LLC now owns 24,361 shares of the biopharmaceutical company’s stock worth $241,000 after acquiring an additional 4,257 shares during the period. 48.79% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

OMER has been the subject of several recent research reports. StockNews.com raised shares of Omeros from a “sell” rating to a “hold” rating in a report on Thursday, March 13th. D. Boral Capital reaffirmed a “buy” rating and issued a $36.00 price objective on shares of Omeros in a report on Thursday, February 20th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Omeros in a research note on Friday, January 17th. Three equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $22.50.

Omeros Stock Performance

Omeros stock opened at $8.52 on Tuesday. The company’s fifty day moving average price is $8.75 and its 200 day moving average price is $7.23. The stock has a market capitalization of $493.73 million, a P/E ratio of -3.69 and a beta of 2.03. Omeros Co. has a 1 year low of $2.61 and a 1 year high of $13.60.

Omeros Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.